New drug trial targets Language-Loss dementia
NCT ID NCT07154485
Summary
This study is testing an experimental drug called NS101 for people with a rare type of dementia that primarily affects language, called semantic variant primary progressive aphasia (svPPA). The main goal is to see if the drug is safe and how the body processes it, while also looking for early signs that it might help control the disease. About 15 participants will receive either the drug or a placebo through an IV to compare the results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA, FRONTOTEMPORAL are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.